Development of Hit to Lead Platform to Accelerate RNA-Targeted Small Molecule Drug Discovery (xFOREST Therapeutics Co., Ltd.)

○ Business Plan

 xFOREST is a leading company in the field, providing solutions to pharmaceutical companies specializing in exploratory processes focused on RNA. Through this grant project, we aim to establish a Hit-to-Lead development platform, creating a foundation for generating lead compounds.

○ Research Outline

 This research project aims to establish a Hit-to-Lead development platform to optimize lead compounds from hit compounds.

①Establishing compound optimization methods specialized for RNA-targeted drug discovery and generating lead compounds.

②Developing a binding selectivity evaluation system to predict off-target toxicity.

③Building compound optimization methods through 3D binding mode analysis of RNA-compound interactions.

City	Year of Establishment	Founder
Kyoto	2020	Shunichi KASHIDA Kaoru Richard KOMATSU

Partner VC	Latest round of Fundraising	Valuation
Miyako Capital	Series A	JPY 8110 million

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	PCA 2024～2027FY	JPY 999 million	United States, Europe

Contact Information :
          tel : 81-075-708-8440
          e-mail : info@xforestx.com

Website : https://www.xforestx.com/

As of November, 2024